Floatz logo

Busulphan

Recurrent Childhood Anaplastic Large Cell Lymphoma

Case Comprehensive Cancer CenterPhase 2Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Recurrent Childhood Anaplastic Large Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Crizotinib
Pfizer
Phase 4BBB
Inno-206
City of Hope Medical Center
Phase 4BBB
Hycamtin
Children's Oncology Group
Phase 2BB
Anti-Thymoglobulin, Rabbit
Roswell Park Cancer Institute
Phase 2B
Eloxatin
National Cancer Institute (NCI)
Phase 1CC

View all 9 →

Same molecule, other indications

Busulphan is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
graft versus host diseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →